RESUMEN
Glutamate, GABA, acetylcholine, dopamine, and serotonin interact with each other to regulate the flow of neural information in the striatum. Serotonin type 1A receptor (5HT1A) is primarily expressed on glutamatergic nerve terminals, and 5HT1B is expressed on GABAergic medium spiny neurons (MSNs). Zonisamide (ZNS) reportedly improves the off period without worsening levodopa-induced dyskinesia (LID) in patients with advanced Parkinson's disease. In this study, LID model rats were prepared by administrating levodopa to unilaterally 6-OHDA-lesioned rats. We analyzed changes in serotonergic neurotransmission of LID model rats to elucidate the relationship between LID and the serotonergic system and pathomechanism of the anti-dyskinetic effects of ZNS. Abnormal involuntary movements (AIMs) were most severe in intermittently levodopa-treated rats but milder in rats intermittently medicated with levodopa and ZNS. Continuously levodopa-infused rats or intermittently ZNS-injected rats did not develop AIMs, and no differences in the expression of brain-derived neurotrophic factor, 5-HT transporter, 5HT1A, and 5HT1B mRNA between the lesioned striatum and normal side were observed. Expression of 5HT1B mRNA was elevated in the lesioned striatum of intermittently levodopa-treated rats, but this elevation was normalized by concomitant use of ZNS. The severity of AIMs was correlated with the ratio of 5HT1B to 5HT1A mRNA expression in the lesioned striatum, indicating that the anti-LID effect of ZNS is based on inhibition via 5HT1B receptors to direct pathway MSNs sensitized by intermittent levodopa treatment. Selectively acting serotonergic drugs, especially those that lower the 5HT1B to 5HT1A ratio, are promising new therapeutic agents to attenuate LID development.
Asunto(s)
Antidiscinéticos/uso terapéutico , Antiparkinsonianos/efectos adversos , Discinesia Inducida por Medicamentos/tratamiento farmacológico , Levodopa/efectos adversos , Neostriado/efectos de los fármacos , Enfermedad de Parkinson Secundaria/tratamiento farmacológico , Neuronas Serotoninérgicas/efectos de los fármacos , Zonisamida/uso terapéutico , Animales , Femenino , Neuronas GABAérgicas/efectos de los fármacos , Oxidopamina , Enfermedad de Parkinson Secundaria/inducido químicamente , Proteínas de Unión al ARN/metabolismo , Ratas , Ratas Sprague-Dawley , Receptor de Serotonina 5-HT1A/efectos de los fármacos , Receptor de Serotonina 5-HT1B/efectos de los fármacos , Serotoninérgicos/uso terapéuticoRESUMEN
OBJECTIVES: The objective of this study is to describe the mechanism of damage to subcortical structures in chronic kidney disease (CKD) and to describe the range of movement disorders associated with CKD. MATERIALS AND METHODS: We have reviewed the Medline literature up to January of 2020 using key words movement disorders and chronic kidney disease. The reviewed articles were studied for mechanisms of subcortical damage in CKD as well as type of the reported movements, their frequency and updated treatment. RESULTS: The search revealed 183 articles most of them dealing with restless legs syndrome. The damage to basal ganglia in CKD resulted from several mechanisms including accumulation of nitro tyrosine caused by reactive oxygen species and action of uremic toxins leading to endothelial damage and dysfunction of blood-brain barrier. Involuntary movements in CKD include restless legs syndrome (RLS), myoclonus, asterixis, dystonia, chorea, tremor, and Parkinsonism. CONCLUSIONS: Chronic kidney disease can cause several abnormal involuntary movements via damaging basal ganglia and subcortical structures. The most common movement disorders in CKD are RLS, myoclonus and asterixis. Restless legs syndrome and myoclonus when severe, need and respond to treatment. Movement disorders in CKD improve with improvement of kidney function.
Asunto(s)
Ganglios Basales/fisiopatología , Riñón/fisiopatología , Trastornos del Movimiento/etiología , Movimiento , Insuficiencia Renal Crónica/complicaciones , Antidiscinéticos/uso terapéutico , Ganglios Basales/efectos de los fármacos , Ganglios Basales/patología , Corea/etiología , Corea/fisiopatología , Discinesias/etiología , Discinesias/fisiopatología , Distonía/etiología , Distonía/fisiopatología , Humanos , Movimiento/efectos de los fármacos , Trastornos del Movimiento/diagnóstico , Trastornos del Movimiento/tratamiento farmacológico , Trastornos del Movimiento/fisiopatología , Mioclonía/etiología , Mioclonía/fisiopatología , Pronóstico , Insuficiencia Renal Crónica/diagnóstico , Insuficiencia Renal Crónica/fisiopatología , Insuficiencia Renal Crónica/terapia , Síndrome de las Piernas Inquietas/etiología , Síndrome de las Piernas Inquietas/fisiopatologíaRESUMEN
BACKGROUND: Botulinum toxin type B (BoNT/B) has been recommended as an alternative for patients who have become resistant to botulinum toxin type A (BoNT/A). This study aimed to compare the clinical effect, within a patient, of four injections with low doses of rimabotulinumtoxinB with the effect of the preceding abobotulinumtoxinA (aboBoNT/A) injections. METHODS: In 17 patients with cervical dystonia (CD) who had become resistant to aboBoNT/A, the clinical effect of the first four rimabotulinumtoxinB (rimaBoNT/B) injections was compared to the effect of the first four aboBoNT/A injections using a global assessment scale and the TSUI score. RESULTS: After the first two BoNT/B injections, all 17 patients responded well and to a similar extent as to the first two BoNT/A injections, but with more side effects such as dry mouth and constipation. After the next BoNT/B injection, the improvement started to decline. The response to the fourth BoNT/B injection was significant (p < 0.048) lower than the fourth BoNT/A injection. Only three patients developed a complete secondary treatment failure (CSTF) and five patients a partial secondary treatment failure (PSTF) after four BoNT/B injections. In nine patients, the usual response persisted. CONCLUSION: With the use of low rimaBoNT/B doses, the induction of CSTF and PSTF to BoNT/B could not be avoided but was delayed in comparison to the use of higher doses. In contrast to aboBoNT/A injections, PSTF and CSTF occurred much earlier, although low doses of rimaBoNT/B had been applied.
Asunto(s)
Antidiscinéticos/uso terapéutico , Toxinas Botulínicas Tipo A/uso terapéutico , Tortícolis/tratamiento farmacológico , Adulto , Anciano , Resistencia a Medicamentos , Sustitución de Medicamentos , Femenino , Humanos , Inyecciones , Masculino , Persona de Mediana Edad , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
Childhood-onset dystonias are a heterogeneously diverse group. There exists a specific set of dystonias that respond profoundly well to low doses of l-dopa (dopa-responsive dystonia [DRD]). Classical DRD is caused by deficiency of GTP cyclohydrolase 1 or tyrosine hydroxylase, but other conditions can cause dystonias that are partially responsive to dopamine. The idea of a diagnostic therapeutic trial with l-dopa for children who present with dystonia has been around for decades and is frequently advocated for; however, l-dopa trials are not without risk.
Asunto(s)
Trastornos Distónicos/diagnóstico , Antidiscinéticos/uso terapéutico , Carbidopa/uso terapéutico , Preescolar , Diagnóstico Diferencial , Combinación de Medicamentos , Trastornos Distónicos/tratamiento farmacológico , Trastornos Distónicos/genética , Humanos , Levodopa/uso terapéutico , MasculinoRESUMEN
l-DOPA is the gold-standard pharmacotherapy for treatment of Parkinson's disease (PD) but can lead to the appearance of troubling dyskinesia which are attributable to 'false neurotransmitter' release of dopamine by serotonergic neurons. Reducing the activity of these neurons diminishes l-DOPA-induced dyskinesia (LID), but there are currently no clinically approved selective, high efficacy 5-HT1A receptor agonists. Here we describe the effects of NLX-112, a highly selective and efficacious 5-HT1A receptor agonist, on LID in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated marmosets, a non-human primate model of PD. NLX-112 exhibited modest plasma half-life (~2h) and marked plasma protein binding (96%). When administered to parkinsonian marmosets with l-DOPA (7 mg/kg p.o.), NLX-112 (0.025, 0.1 and 0.4 mg/kg p.o.) reduced LID scores at early time-points after administration, whilst only minimally interfering with the l-DOPA-induced reversal of motor disability. In contrast, the prototypical 5-HT1A receptor agonist, (+)8-OH-DPAT (0.6 and 2 mg/kg p. o.), reduced LID but also abolished l-DOPA's anti-disability activity. Administered by itself, NLX-112 (0.1, 0.2 mg/kg p.o.) produced very little dyskinesia or locomotor activity, but reduced motor disability scores by about half the extent elicited by l-DOPA, suggesting that it may have motor facilitation effects of its own. Both NLX-112 and (+)8-OH-DPAT induced unusual and dose-limiting behaviors in marmoset that resembled 'serotonin behavioral syndrome' observed previously in rat. Overall, the present study showed that NLX-112 has anti-LID activity at the doses tested as well as reducing motor disability. The data suggest that additional investigation of NLX-112 is desirable to explore its potential as a treatment for PD and PD-LID.
Asunto(s)
Antidiscinéticos/uso terapéutico , Antiparkinsonianos/uso terapéutico , Discinesia Inducida por Medicamentos/tratamiento farmacológico , Intoxicación por MPTP/tratamiento farmacológico , Piperidinas/uso terapéutico , Piridinas/uso terapéutico , Agonistas del Receptor de Serotonina 5-HT1/uso terapéutico , Animales , Antidiscinéticos/farmacología , Antiparkinsonianos/farmacología , Callithrix , Discinesia Inducida por Medicamentos/metabolismo , Discinesia Inducida por Medicamentos/fisiopatología , Femenino , Levodopa/toxicidad , Locomoción/efectos de los fármacos , Locomoción/fisiología , Intoxicación por MPTP/metabolismo , Intoxicación por MPTP/fisiopatología , Masculino , Piperidinas/farmacología , Piridinas/farmacología , Receptor de Serotonina 5-HT1A/metabolismo , Agonistas del Receptor de Serotonina 5-HT1/farmacología , Resultado del TratamientoRESUMEN
Recently, the herbal medicine Ukgansan (Yigansan in China, Yokukansan in Japan) was reported to be effective in the management of movement disorders. We report the case of a 62-year-old woman with herpes simplex encephalitis exhibiting atypical abnormal movements in the chronic stage. While controlling the abnormal movements with haloperidol, an antipsychotic agent, we prescribed Ukgansan-gami, an extract of a variant of Ukgansan, at a dose of 12â¯g/day to prevent the recurrence of abnormal movements and allow for the discontinuation of haloperidol. The patient was successfully treated with Ukgansan-gami, with no further recurrence of symptoms, making the use of haloperidol no longer necessary. The potential mechanism of action of Ukgansan involves the inhibition of nervous system hyperexcitability through the suppression of glutamate sodium channels, as well as attenuation of hypermotility through serotonin regulation. The present case suggests that herbal medicine therapy was likely to be an alternative to antipsychotics.
Asunto(s)
Antidiscinéticos/uso terapéutico , Medicamentos Herbarios Chinos/uso terapéutico , Discinesias/tratamiento farmacológico , Encefalitis por Herpes Simple/tratamiento farmacológico , Femenino , Haloperidol/uso terapéutico , Humanos , Persona de Mediana EdadRESUMEN
Botulinum toxin type A (BoNT-A) injections in children with cerebral palsy (CP) may negatively affect muscle growth and strength. We injected BoNT-A into the affected limbs of 14 children (4.57 ± 2.28 years) with hemiplegic CP and exhibiting tip-toeing gait on the affected side and investigated the morphological alterations in the medial head of the gastrocnemius muscle (GCM). We assessed thickness of the GCM, fascicle length, and fascicle angle on the affected and unaffected sides at baseline at 4 and 12 weeks after BoNT-A injections. The primary outcome measure was the change (percentage) in GCM thickness in the affected side treated with BoNT-A in comparison with the unaffected side. The percentage of treated GCM thickness became significantly thinner at 4 and 12 weeks after BoNT-A injection than baseline. However, the percentage of fascicle length and angle in treated limbs showed no significant change from baseline 4 and 12 weeks after the injection. BoNT-A injections might reduce muscle thickness in children with spastic hemiplegic CP. Fascicle length and angle might not be affected by BoNT-A injections after correction of normal growth of the children.
Asunto(s)
Antidiscinéticos/uso terapéutico , Toxinas Botulínicas/uso terapéutico , Parálisis Cerebral/tratamiento farmacológico , Extremidades/crecimiento & desarrollo , Extremidades/patología , Hemiplejía/tratamiento farmacológico , Adolescente , Parálisis Cerebral/complicaciones , Parálisis Cerebral/patología , Niño , Preescolar , Extremidades/diagnóstico por imagen , Femenino , Lateralidad Funcional , Trastornos Neurológicos de la Marcha/diagnóstico por imagen , Trastornos Neurológicos de la Marcha/tratamiento farmacológico , Trastornos Neurológicos de la Marcha/etiología , Hemiplejía/etiología , Hemiplejía/patología , Humanos , Masculino , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/crecimiento & desarrollo , Resultado del Tratamiento , UltrasonografíaRESUMEN
OBJECTIVE: To evaluate the long-term safety and efficacy of deutetrabenazine in patients with tardive dyskinesia (TD). METHOD: Patients with TD who completed the 12 week, phase 3, placebo-controlled trials were eligible to enter this open-label, single-arm study. The open-label study consisted of a 6 week dose-escalation phase and a long-term maintenance phase (clinic visits at Weeks 4, 6 and 15, and every 13 weeks until Week 106). Patients began deutetrabenazine at 12 mg/day, titrating up to a dose that was tolerable and provided adequate dyskinesia control, based on investigator judgement, with a maximum allowed dose of 48 mg/day (36 mg/day for patients taking strong cytochrome P450 2D6 (CYP2D6) inhibitors). Safety measures included incidence of adverse events (AEs) and scales used to monitor parkinsonism, akathisia/restlessness, anxiety, depression, suicidality and somnolence/sedation. Efficacy endpoints included the change in Abnormal Involuntary Movement Scale (AIMS) score (items 1 to 7) from baseline and the proportion of patients rated as 'Much Improved' or 'Very Much Improved' on the Clinical Global Impression of Change. RESULTS: A total of 343 patients enrolled in the extension study, and there were 331 patient-years of exposure in this analysis. The exposure-adjusted incidence rates of AEs with long-term treatment were comparable to or lower than those observed in the phase 3 trials. The mean (SE) change in AIMS score was -4.9 (0.4) at Week 54 (n = 146), - 6.3 (0.7) at Week 80 (n = 66) and -5.1 (2.0) at Week 106 (n = 8). CONCLUSIONS: Overall, long-term treatment with deutetrabenazine was efficacious, safe, and well tolerated in patients with TD. TRIAL REGISTRATION NUMBER: NCT02198794.
Asunto(s)
Antidiscinéticos/uso terapéutico , Discinesia Tardía/tratamiento farmacológico , Tetrabenazina/análogos & derivados , Adulto , Anciano , Antidiscinéticos/efectos adversos , Antipsicóticos/efectos adversos , Inhibidores del Citocromo P-450 CYP2D6/efectos adversos , Inhibidores del Citocromo P-450 CYP2D6/uso terapéutico , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Trastornos del Humor/complicaciones , Trastornos del Humor/tratamiento farmacológico , Trastornos Psicóticos/complicaciones , Trastornos Psicóticos/tratamiento farmacológico , Discinesia Tardía/fisiopatología , Tetrabenazina/efectos adversos , Tetrabenazina/uso terapéutico , Resultado del TratamientoRESUMEN
We present a case of hemichorea/hemiballism, a rare complication of hyperglycemia. Diagnosis is made clinically by signs of unilateral involuntary movements of the extremities combined with typical neuroradiological findings in the basal ganglia. Guidelines for treatment of the condition are lacking but in many cases correction for hyperglycemia is sufficient for full symptom relief. In other cases, symptomatic treatment with haloperidol and tetrabenazine can be used.
Asunto(s)
Corea/etiología , Discinesias/etiología , Hiperglucemia/complicaciones , Anciano de 80 o más Años , Antidiscinéticos/uso terapéutico , Ganglios Basales/diagnóstico por imagen , Ganglios Basales/patología , Corea/tratamiento farmacológico , Discinesias/tratamiento farmacológico , Femenino , Haloperidol/uso terapéutico , Humanos , Hiperglucemia/diagnóstico por imagen , Hiperglucemia/terapia , Imagen por Resonancia Magnética , Tomografía Computarizada por Rayos XRESUMEN
BACKGROUND: The mechanisms by which spasticity reductions after botulinum toxin A (BoNT) affect gait in stroke are not well understood. We systematically reviewed the effects of BoNT on spatiotemporal, kinematic, kinetic and electromyographic (EMG) measures during gait. QUESTION: What are the effects of botulinum toxin on gait mechanics in stroke patients? METHODS: Systematic search using PubMed and Web of Science. We considered all studies that reported laboratory-based and instrumented gait measures as primary or secondary outcomes to determine the effects of BoNT on walking performance in stroke populations only. Selected studies were classified and analysed based on the injection sites. RESULTS: A total of 240 articles were identified of which 22 were selected for analysis. Overall, 91% of the studies reported spatiotemporal, 64% kinematics, 23% kinetics, 32% EMG and 23% other gait measures. All but one study found significant effects of BoNT on gait measures using instrumented assessments even when clinical measures (i.e. speed) did not significantly improve. However, the majority of the studies had a high risk of bias. Overall, BoNT improved: a) dorsiflexion during stance, propulsive forces and timing and activity of more proximal musculature with injections in the plantarflexors; b) hip, knee and ankle angles and velocities, coordination and energetic cost with injections in the rectus femoris; c) segmental coordination and energetic cost when several lower limb muscles were injected; and, d) elbow and trunk angles when upper limb muscles were injected. CONCLUSION: Instrumented and laboratory measures of gait improve after BoNT injections in different muscle groups even in the absence of clinical changes.
Asunto(s)
Antidiscinéticos/uso terapéutico , Toxinas Botulínicas Tipo A/uso terapéutico , Trastornos Neurológicos de la Marcha/tratamiento farmacológico , Marcha/efectos de los fármacos , Accidente Cerebrovascular , Velocidad al Caminar , Antidiscinéticos/administración & dosificación , Antidiscinéticos/farmacología , Toxinas Botulínicas Tipo A/administración & dosificación , Toxinas Botulínicas Tipo A/farmacología , Humanos , Inyecciones IntramuscularesRESUMEN
BACKGROUND: Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes, the most common maternally inherited mitochondrial disease, can present with a wide range of neurological manifestations including both central and peripheral nervous system involvement. The most frequent genetic mutation reported in mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome is A3243G in MT-TL1 gene. Stroke-like episodes, dementia, epilepsy, lactic acidemia, myopathy, recurrent headaches, hearing impairment, diabetes, and short stature constitute the known presentations in this syndrome. Among the abnormal involuntary movements in mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome, myoclonus is the commonest. Other movement disorders, including chorea, are rarely reported in this disorder. CASE PRESENTATION: A 14-year-old South Asian boy from rural Bengal (India), born of a second degree consanguineous marriage, with normal birth and development history, presented with abnormal brief jerky movements involving his trunk and limbs, with recurrent falls for 10 months. We present here a case of heteroplasmic mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome with A3251G mutation, in which the clinical picture was dominated by a host of involuntary abnormal movements including chorea-ballism, myoclonus, and oromandibular dystonia in a backdrop of cognitive decline, seizure, and stroke-like episode. A final diagnosis was established by muscle biopsy and genetic study. Haloperidol was administered to control the involuntary movements along with introduction of co-enzyme Q, besides symptomatic management for his focal seizures. Six months into follow-up his seizures and abnormal movements were controlled significantly with slight improvement of cognitive abilities. CONCLUSION: The dominance of hyperkinetic movements in the clinical scenario and the finding of a point mutation A3251G in MT-TL1 gene make this a rare presentation.
Asunto(s)
Antidiscinéticos/uso terapéutico , Corea/diagnóstico , ADN Mitocondrial/genética , Haloperidol/uso terapéutico , Síndrome MELAS/diagnóstico , Mutación Puntual/genética , Adolescente , Corea/genética , Corea/fisiopatología , Pruebas Genéticas , Humanos , Síndrome MELAS/tratamiento farmacológico , Síndrome MELAS/genética , Síndrome MELAS/fisiopatología , Masculino , Micronutrientes/uso terapéutico , Resultado del Tratamiento , Ubiquinona/uso terapéuticoAsunto(s)
Corea/diagnóstico por imagen , Anciano de 80 o más Años , Antidiscinéticos/uso terapéutico , Corea/tratamiento farmacológico , Corea/etiología , Haloperidol/uso terapéutico , Humanos , Coma Hiperglucémico Hiperosmolar no Cetósico/complicaciones , Masculino , Tomografía Computarizada por Rayos XAsunto(s)
Diabetes Mellitus Tipo 2/complicaciones , Discinesias/etiología , Antidiscinéticos/uso terapéutico , Ganglios Basales/diagnóstico por imagen , Ganglios Basales/lesiones , Glucemia/efectos de los fármacos , Clonazepam/uso terapéutico , Discinesias/diagnóstico , Discinesias/tratamiento farmacológico , Femenino , Haloperidol/uso terapéutico , Humanos , Persona de Mediana EdadAsunto(s)
Humanos , Masculino , Anciano de 80 o más Años , Corea/tratamiento farmacológico , Tomografía Computarizada por Rayos X , Corea/etiología , Corea/diagnóstico por imagen , Antidiscinéticos/uso terapéutico , Haloperidol/uso terapéutico , Coma Hiperglucémico Hiperosmolar no Cetósico/complicacionesAsunto(s)
Antidiscinéticos/farmacología , Antidiscinéticos/uso terapéutico , Discinesia Inducida por Medicamentos/tratamiento farmacológico , Trastornos Parkinsonianos/tratamiento farmacológico , Agonistas del Receptor de Serotonina 5-HT1/farmacología , Animales , Antidiscinéticos/efectos adversos , Discinesia Inducida por Medicamentos/metabolismo , Humanos , Trastornos Parkinsonianos/metabolismo , Serotonina/metabolismo , Agonistas del Receptor de Serotonina 5-HT1/uso terapéuticoRESUMEN
INTRODUCTION: Botulinum toxin (BoNT) is the first line therapy for cervical dystonia (CD), with most patients receiving many treatment sessions, and so come to recognize and expect the benefits and harms of BoNT, making it difficult to separate which adverse events (AEs) are driven by BoNT and which come from patients' expectations. METHODS: Using the results of three Cochrane systematic reviews of randomized controlled trials (RCTs) we pooled results to calculate the risk of general and specific AEs associated with BoNT, and the proportion of AEs that cannot be pharmacologically attributed to BoNT. RESULTS: Fifteen RCTs, enrolling 1604 patients, were included. BoNT was associated with an increased risk of AEs, but 79% of this increased risk cannot be pharmacologically attributed to BoNT. CONCLUSIONS: Patients with CD attach a considerable expectation of harm due to BoNT, reflected in the large proportion of non-pharmacologically-mediated AEs.
Asunto(s)
Toxinas Botulínicas Tipo A/efectos adversos , Fármacos Neuromusculares/efectos adversos , Tortícolis/tratamiento farmacológico , Antidiscinéticos/efectos adversos , Antidiscinéticos/uso terapéutico , Toxinas Botulínicas Tipo A/uso terapéutico , Trastornos de Deglución/inducido químicamente , Humanos , Debilidad Muscular/inducido químicamente , Fármacos Neuromusculares/administración & dosificación , Efecto Placebo , Ensayos Clínicos Controlados Aleatorios como Asunto/métodos , Tortícolis/diagnóstico , Resultado del TratamientoRESUMEN
BACKGROUND: Cerebral palsy occurs in up to 2.1 of every 1000 live births and encompasses a range of motor problems and movement disorders. One commonly occurring movement disorder amongst those with cerebral palsy is dystonia: sustained or intermittent involuntary muscle spasms and contractions that cause twisting, repetitive movements and abnormal postures. The involuntary contractions are often very painful and distressing and cause significant limitations to activity and participation.Oral medications are often the first line of medical treatment for dystonia. Trihexyphenidyl is one such medication that clinicians often use to treat dystonia in people with cerebral palsy. OBJECTIVES: To assess the effects of trihexyphenidyl in people with dystonic cerebral palsy, according to the World Health Organization's (WHO) International Classification of Functioning, Disability and Health (ICF) domains of impairment, activity and participation. We also assessed the type and incidence of adverse effects in people taking the drug. SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, eight other databases and two trials registers in May 2017, and we checked reference lists and citations to identify additional studies. SELECTION CRITERIA: We included randomised controlled trials comparing oral trihexyphenidyl versus placebo for dystonia in cerebral palsy. We included studies in children and adults of any age with dystonic cerebral palsy, either in isolation or with the associated movement disorders of spasticity, ataxia, chorea, athetosis and/or hypotonia. We included studies regardless of whether or not the study authors specified the method used to diagnose dystonia in their study population. Primary outcomes were change in dystonia and adverse effects. Secondary outcomes were: activity, including mobility and upper limb function; participation in activities of daily living; pain; and quality of life. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. MAIN RESULTS: We identified one study, which was set in Australia, that met the inclusion criteria. This was a randomised, double-blind, placebo-controlled, cross-over trial in 16 children (10 boys and 6 girls) with predominant dystonic cerebral palsy and a mean age of 9 years (standard deviation 4.3 years, range 2 to 17 years). We considered the trial to be at low risk of selection, performance, detection, attrition, reporting and other sources of bias. We rated the GRADE quality of the evidence as low.We found no difference in mean follow-up scores for change in dystonia as measured by the Barry Albright Dystonia Scale (BADS), which assesses eight body regions for dystonia on a 5-point scale (0 = none to 4 = severe), resulting in a total score of 0 to 32. The BADS score was 2.67 points higher (95% confidence interval (CI) -2.55 to 7.90; low-quality evidence), that is, worse dystonia, in the treated group. Trihexyphenidyl may be associated with an increased risk of adverse effects (risk ratio 2.54, 95% CI 1.38 to 4.67; low-quality evidence).There was no difference in mean follow-up scores for upper limb function as measured by the Quality of Upper Extremity Skills Test, which has four domains that collectively assess 36 items (each scored 1 or 2) and produces a total score of 0 to 100. The score in the treated group was 4.62 points lower (95% CI -10.98 to 20.22; low-quality evidence), corresponding to worse function, than in the control group. We found low-quality evidence for improved participation (as represented by higher scores) in the treated group in activities of daily living, as measured by three tools: 18.86 points higher (95% CI 5.68 to 32.03) for the Goal Attainment Scale (up to five functional goals scored on 5-point scale (-2 = much less than expected to +2 = much more than expected)), 2.91 points higher (95% CI 1.01 to 4.82) for the satisfaction subscale of the Canadian Occupational Performance Measure (COPM; satisfaction with performance in up to five problem areas scored on a 10-point scale (1 = not satisfied at all to 10 = extremely satisfied)), and 2.24 points higher (95% CI 0.64 to 3.84) for performance subscale of the COPM (performance in up to five problem areas scored on a 10-point scale (1 = not able to do to; 10 = able to do extremely well)).The study did not report on pain or quality of life. AUTHORS' CONCLUSIONS: At present, there is insufficient evidence regarding the effectiveness of trihexyphenidyl for people with cerebral palsy for the outcomes of: change in dystonia, adverse effects, increased upper limb function and improved participation in activities of daily living. The study did not measure pain or quality of life. There is a need for larger randomised, controlled, multicentre trials that also examine the effect on pain and quality of life in order to determine the effectiveness of trihexyphenidyl for people with cerebral palsy.
Asunto(s)
Antidiscinéticos/uso terapéutico , Parálisis Cerebral/complicaciones , Distonía/tratamiento farmacológico , Trihexifenidilo/uso terapéutico , Adolescente , Niño , Preescolar , Distonía/etiología , Femenino , Humanos , MasculinoRESUMEN
Non-ketotic hyperglycaemic hemichorea-hemiballismus (NHHH) is commonly seen among elderly Asian women with type 2 diabetes mellitus. Here, we present a case of a 16-year-old Filipina with type 1 diabetes mellitus who is poorly compliant to her medications and subsequently developed right hemichorea-hemiballismus (HH). She was initially admitted with hyperglycaemia but was negative for ketonuria or metabolic acidosis. Neuroimaging showed bilateral lentiform nuclei and left caudate hyperdensities on CT and T1-weighted hyperintensity on MRI. Blood glucose was controlled with insulin. Haloperidol and clonazepam were started for the HH with gradual resolution of symptoms in 6 weeks. This is the fifth reported case of NHHH seen among the paediatric age group. NHHH in the paediatric population is clinically and radiographically similar to NHHH seen among adults. Correction of hyperglycaemia results in clinical improvement and radiographic resolution of lesions but persistent cases may necessitate specific treatment targeted towards the abnormal movements.
Asunto(s)
Antidiscinéticos/uso terapéutico , Corea/diagnóstico , Diabetes Mellitus Tipo 1/complicaciones , Discinesias/diagnóstico , Hipoglucemiantes/uso terapéutico , Insulina/uso terapéutico , Adolescente , Glucemia , Corea/sangre , Corea/tratamiento farmacológico , Corea/etiología , Clonazepam/uso terapéutico , Diabetes Mellitus Tipo 1/sangre , Diabetes Mellitus Tipo 1/fisiopatología , Discinesias/sangre , Discinesias/tratamiento farmacológico , Discinesias/etiología , Femenino , Haloperidol/uso terapéutico , Humanos , Insulina/sangre , Neuroimagen , Cooperación del Paciente , Tomografía Computarizada por Rayos X , Resultado del TratamientoRESUMEN
RATIONALE: Hyperglycemic hemichorea tends to affect elderly patients with type 2 diabetes, women, and the Asian population. The onset of involuntary movement typically occurs at the hyperglycemic state and subsides at the euglycemic state. In this report, we present an unusual case that developed delayed-onset hemichorea after hyperglycemia correction. PATIENT CONCERNS: A 70-year-old man was admitted to neurology ward with symptoms of subacute dizziness. Hyperglycemia and high level ketone body was incidentally noted. Hemichorea occurred in his left limbs 2 days after hyperglycemia correction. DIAGNOSES: Patient remained conscious, and no other focal neurological deficits were noted while hemichorea occurred. Blood test revealed no contributory cause. Brain magnetic resonance imaging revealed no lesions in the putamen or subthalamus. A diagnosis of probable hyperglycemia-related hemichorea was made. INTERVENTIONS: Haloperidol (2âmg, 3 times per day) was prescribed. OUTCOMES: Hemichorea improved gradually before discharge and resolved 4 months later. LESSONS: Differential diagnosis of hemichorea should include delayed-onset hemichorea after hyperglycemia correction.
Asunto(s)
Antidiscinéticos/uso terapéutico , Discinesias/etiología , Haloperidol/uso terapéutico , Hiperglucemia/complicaciones , Anciano , Diagnóstico Diferencial , Discinesias/diagnóstico , Discinesias/tratamiento farmacológico , Humanos , Imagen por Resonancia Magnética , MasculinoRESUMEN
Among the neurological manifestations of systemic lupus erythematosus (SLE), chorea is rare, presenting in less than 7% of the pediatric SLE patients. It can appear early in the onset of SLE, be the first or even the sole clinical feature of the illness and has strongly been associated with the presence of antiphospholipid antibodies. We report on the case of a 13-year old boy, admitted with acute onset chorea and finally diagnosed with SLE. Subsequently, we present a short review of the literature on the epidemiology, suggested pathogenesis, clinical presentation and treatment of this rare presentation of SLE.